Invention herewith described refers to the preparation of the biocompatible micro-emulsion systems having the physicochemical and biopharmaceutical properties of pharmaceutical compositions for topical application with the controlled and/or sustained release of ibuprofen, which is desirable as a prerequisite for maintaining the therapeutic concentration at the site of therapeutic action throughout the complete dosing interval that can be significantly prolonged compared to the conventional medical products. The micro emulsion systems that are the subject of this invention in their structure in addition to Ibuprofen (5%) contain the surfactant (0% - 20%) (the surface-active substance, type Caprylocaproyl macrogolglycerides (EP) or lecithin of vegetable origin), the cosurfactant (0% -55%) (the surface-active substance from the group of alkylphenol ethoxylates (APEO), polysorbates, polyethoxylated derivatives of hydrogenated castor oil and/or poloxamers), the oil phase (ester of C14-C22 monocarboxylic acids and short-chain monohydric alcohols (0%-10%) or vegetable oil (0%-15%)) and an aqueous phase which in addition to purified water (20%-60%) may also contain the viscosity-increasing agent from the group of hydrocolloids (0% -1.5%) and a preservative (0%-0.2%). The invention also provides the methods for the preparation thereof.Pronalazak se odnosi na dobijanje biokompatibilnih mikroemulzionih sistema koji imaju fizičko-hemijske i biofarmaceutske karakteristike farmaceutskih preparata za lokalnu primenu sa kontrolisanim i/ili produženim oslobađanjem ibuprofena, koje je poželjno kao preduslov za održavanje terapijske koncentracije na mestu delovanja tokom celokupnog intervala doziranja koji može da se značajno prolongira u poređenju sa konvencionalnim medicinskim proizvodima. Mikroemulzioni sistemi koji su predmet pronalaska u svom sastavu pored ibuprofena (5%) sadrže: surfaktant (0%-20%) (površinski aktivnu supstancu tipa kaprilokapril makrogolglicerida ili lecitina b
